This Phase I clinical trial (n=36) of sublingual 5-MeO-DMT (6-12 mg weekly doses over four weeks) in adults with moderate to high anxiety/depression demonstrated good safety and tolerability with no significant adverse events, rapid absorption with peak plasma concentrations at 20 minutes, dose-dependent neurophysiological modulation without full psychedelic effects, and maintenance of normal cognitive and behavioral function.| Microdosing Institute
At Microdosing Institute, we bring you the highest quality, research-backed microdosing education, community support, and recent research findings.| Microdosing Institute
Microdosing Podcast w/ Marijn Schrieken – Your Body As Your Teacher | Microdosing Institute
Discover Vereniging Microdosing Nederland, founded with Microdosing Institute, uniting coaches, producers & researchers for safe microdosing in the Netherlands.| Microdosing Institute
This re-analysis of a Phase I RCT (n=80) examines the pharmacokinetics (how the body affects a drug) of LSD microdosing (10µg; 14x; 6w) in healthy adult males. The study established a one-compartment pharmacokinetic model showing an elimination half-life of 3.08h, found minimal physiological effects (| Microdosing Institute
This study explores the effects of LSD microdosing on ADHD, revealing safety but no significant benefits over placebo.| Microdosing Institute
Join the Microdosing Institute community and engage with others to share experiences, insights, and well-being strategies.| Microdosing Institute
This systematic review (s=31) examines the side effects of microdosing LSD and psilocybin, finding that adverse effects are typically dose-dependent, mild, and short-lived. Common side effects include increased blood pressure, anxiety, and cognitive impairment. The review highlights the lack of standardised reporting on side effects and calls for future studies to provide more systematic and transparent assessments.| Microdosing Institute
This online survey (n=6,193; 2,488 microdosers) examines differences between exclusive microdosers and those who use both micro and macrodoses of psychedelics. The study finds exclusive microdosers were typically older, more likely to be female and non-Caucasian, with psilocybin (74.5%) and LSD (34.4%) being the most commonly used substances, primarily for general wellbeing (73.0%).| Microdosing Institute
This randomised feasibility study (n=37) evaluates psilocybin-assisted (microdoses x 6) frontal-midline theta neurofeedback (NF) to improve executive functions (EFs) in participants with psychiatric disorders. Despite no significant improvements in tasks-based EFs, the experimental group reported medium to high gains in daily EFs, indicating the potential benefits of this neuromodulation technique for enhancing daily functioning.| Microdosing Institute
Discover how the setting affects psilocybin microdosing, influencing emotional and cognitive responses for a balanced experience.| Microdosing Institute